57475-17-9
Chemical Structure
Brovincamine
- CAS No.: 57475-17-9
- Formula:C21H25BrN2O3
- Molecular Weight:433.35
IUPAC Name: methyl (41S,12S,13aS)-9-bromo-13a-ethyl-12-hydroxy-2,3,41,5,6,12,13,13a-octahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate
InChIKey: WYIJGAVIVKPUGJ-GIVPXCGWSA-N
SMILES: C(C)[C@]12[C@]3(C=4N(C=5C(C4CCN3CCC1)=CC=C(Br)C5)[C@](C(OC)=O)(O)C2)[H]
Biological Activity: Brovincamine is an orally active slow Ca2+ channel blocker and vasodilator. Brovincamine reduces Ca2+ influx across the plasma membrane by blocking Ca2+ channels. Brovincamine inhibits catecholamine secretion, cholinergic function, autonomic parasympathetic nervous system activity, cerebrovascular resistance, and nerve stimulation-induced convulsive responses. Brovincamine induces cerebrovascular, coronary, and intracranial vasodilation, improves cerebral cortical microcirculation, enhances cerebral metabolic activity, and increases capillary clearance efficiency. Brovincamine can be used in research related to cerebral ischemic diseases, cardiac ischemic diseases, and normal-tension glaucoma[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Brovincamine | Brovincamine is an orally active slow Ca2+ channel blocker and vasodilator. Brovincamine reduces Ca2+ influx across the plasma membrane by blocking Ca2+ channels. Brovincamine inhibits catecholamine secretion, cholinergic function, autonomic parasympathetic nervous system activity, cerebrovascular resistance, and nerve stimulation-induced convulsive responses. Brovincamine induces cerebrovascular, coronary, and intracranial vasodilation, improves cerebral cortical microcirculation, enhances cerebral metabolic activity, and increases capillary clearance efficiency. Brovincamine can be used in research related to cerebral ischemic diseases, cardiac ischemic diseases, and normal-tension glaucoma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Morita K, et al. Inhibitory action of brovincamine on catecholamine secretion from cultured bovine adrenal medullary cells: possible relation to its blocking action on Ca2+ channels. Biochem Pharmacol. 1991 Jun 21;42(1):190-2.
- [2]. Kushiku K, et al. Effects of brovincamine on the autonomic nervous function in the dog and rat. Journal of pharmacobio-dynamics. 1984 Mar;7(3):177-85.
- [3]. Sawada A, et al. Prevention of visual field defect progression with brovincamine in eyes with normal-tension glaucoma. Ophthalmology. 1996 Feb;103(2):283-8.
- [4]. Meier-Ruge W, et al. Effects of brovincamine on the stereological parameters of corticocerebral capillaries. Life sciences. 1987 Mar 09;40(10):943-9.
